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INTRODUCTION 
       Chronic kidney disease (CKD) encompasses a spectrum of 
different pathophysiologic processes associated with abnormal kidney 
function, and a progressive decline in glomerular filtration rate (GFR). 
CKD affects virtually every organ system of the body, resulting in an 
increase in morbidity and mortality. 
       Cardiovascular disease is the leading cause of morbidity and 
mortality in patients at every stage of CKD. Emerging evidence 
indicates that the function of these two organ systems are affected by 
each other in a complex interplay. The incremental risk of 
cardiovascular disease in those with CKD compared to the age- and 
sex-matched general population ranges from 10- to 200-fold, 
depending on the stage of CKD. Between 30 and 45% of patients 
reaching stage 5 CKD already have advanced cardiovascular 
complications. As a result, most patients with CKD succumb to 
cardiovascular disease  before ever reaching stage 5 CKD. 
    . Most patients with CKD suffer frequently from cardiac 
abnormalities including left ventricular hypertrophy (LVH), left 
ventricular dilatation (LVD), left ventricular (LV) diastolic and/or 
systolic dysfunction. Left ventricular hypertrophy(LVH) is one of the 
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strongest risk factors for cardiovascular morbidity and mortality in 
patients with CKD.  
Hypertension is one of the most common complications of CKD. 
It usually develops early during the course of CKD and is associated 
with adverse outcomes, including the development of ventricular 
hypertrophy and a more rapid loss of renal function. Uncontrolled 
hypertension accelerates the rapid worsening of cardiac function and 
results in more severe grades of left ventricular hypertrophy. 
      The cardiorenal syndrome, defined as the confluence of cardiac 
and renal impairment, has been recognized as a known entity in which 
not only do cardiac and renal dysfunction coexist, but the failure of one 
system accelerates the decline of the other. 
     The present study was aimed at assessing cardiac function in 
patients with varying stages of CKD in non diabetics and non smokers. 
Echocardiography is a simple and non invasive tool to assess LV mass 
and systolic and diastolic dysfunction in these patients. The study 
further assesses the effect of uncontrolled hypertension in these 
patients. 
    The study is aimed further in assessing the advent of Tissue Doppler 
Imaging (TDI) in assessing diastolic dysfunction as compared to 
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conventional echocardiography.  The study further compares the 
different modalities of measurement of LV mass in these patients. 
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REVIEW OF LITERATURE 
     Chronic kidney disease is a pathophysiologic process with multiple 
etiologies existing for more than 3 months resulting in inexorable 
attrition of nephron number and function frequently leading to end 
stage renal disease (ESRD). 
     Chronic kidney disease (CKD) is a global threat to health in general 
and for developing countries in particular, because therapy is 
expensive and life-long. In India, ∼90% patients cannot afford the 
cost. 
    The epidemiology of CKD in India is very different from the West. 
Patients are roughly two decades younger, and a substantial proportion 
present with small kidneys, so the aetiology of CKD is unclear1. The 
aetiology of these epidemiologic differences is unknown. Probably a 
correlation does exist between low birth weight  and  diminished  
nephron   number2 .  
    In one study conducted by Charumathi Sabanayagam3 concerning 
the ethnic disparities in CKD, it was found that older age and the 
presence of diabetes, hypertension and dyslipidaemia were 
significantly associated with CKD in all ethnic groups. Clinical, 
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metabolic, socioeconomic and behavioural factors accounted for 78% 
of excess risk of CKD in Indians. Hypertension contributes to 23% of 
greater population-attributable risk of CKD.  
      In another study, variations in Th1/Th2 regulatory lymphocyte 
balance and relationship to glomerulonephritis as postulated by the 
'Hygiene hypothesis'4 has been proposed as a contributing factor.                                      
        Another hypothesis proposed is the 'Asian Indian Phenotype' or 
'Thrifty Phenotype' of truncal/visceral obesity and insulin resistance5.     
      In one study conducted by All India Institute of medical sciences6, 
the prevalence of CKD in India is ∼0.8%. Diabetes has emerged as the 
most frequent cause (30–40%) followed by hypertension (14–22%), 
chronic glomerulonephritis (16–20%), chronic interstitial nephritis 
(5.4–12.7%), heredofamilial disease (8.4%) and obstruction including 
calculus (2.9%) . 
        In 2005, the Indian Journal of Nephrology adopted the National 
Kidney Foundation- Kidney Dialysis Outcome Quality Initiative 
(NKF-KDOQI)7 and European Best  Guidelines as a template to 
compile guidelines for management of CKD and pre-ESRD patients in 
India. For purposes of staging CKD, current guidelines recommend 
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two methods for measuring estimated glomerular filtration rate 
(eGFR). These include the Cockgroft Gault equation and equation 
from the modification of diet in renal disease (MDRD). 
Cockgroft Gault equation :  
Creatinine    (140-age) x bodyweight (kg) 
clearance =      x 0.85 (for women) 
   72 x S.creat (mg/dl)  
MDRD formula :  
               The Modification of Diet in Renal Disease (MDRD) study 
was a multicenter, controlled trial that evaluated the effect of dietary 
protein restriction and strict blood pressure control on the progression 
of renal disease. From this study, it was determined that older age and 
female sex were independent predictors of GFR, reflecting the well-
known relation of age and sex to muscle mass. GFR was further 
adjusted for body surface area so that neither height nor weight was an 
independent predictor of adjusted GFR. African American ethnicity 
was an independent predictor of higher GFR as on average, black 
persons have greater muscle mass than whites. 
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Estimated GFR (mL/min per 1.73 m2) = 1.86 x (PCr)–1.154 x (age)–
0.203 
  Multiply by 0.742 for women,  Multiply by 1.21 for African 
Americans                                                           
There are some limitations of this calculated GFR. It may not be 
accurate if kidney function is fluctuating and not in a steady state or in 
cases where muscle mass is abnormal. The GFR estimate may be 
inaccurate in extremes of age and in patients with severe malnutrition 
or obesity, paraplegia or quadriplegia, and in pregnant women. The 
MDRD equation is inaccurate for patients on drugs and with conditions 
that interfere with creatinine secretion (for example, cimetidine or 
trimethoprim) or creatinine assay (for example, diabetic ketoacidosis). 
In these cases, a 24-hour creatinine clearance may be necessary to 
accurately estimate kidney function. 
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NKF KDOQI STAGING7 : 
TABLE 1 
Classification of Chronic Kidney Disease (CKD)
Stage eGFR 
0 >90a 
1 >=90b
2 60–89 
3 30–59 
4 15–29 
5 <15 
 
a With risk factors for ckd. b With demonstrated kidney damage (e.g., 
persistent proteinuria, abnormal urine sediment, abnormal blood and 
urine chemistry, abnormal imaging studies. 
            The normal annual mean decline in GFR with age from the 
peak GFR (~120 mL/min per 1.73 m2) attained during the third decade 
of life is ~1 mL/min per year per 1.73 m2, reaching a mean value of 70 
mL/min per 1.73 m2 at age 70. The mean GFR is lower in women than 
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in men. For example, a woman in her 80s with a normal serum 
creatinine may have a GFR of just 50 mL/min per 1.73 m2. Thus, even 
a mild elevation in serum creatinine concentration [for ex (1.5 
mg/dL)], often signifies a substantial reduction in GFR in most 
individuals. Persistence in the urine of >17 mg of albumin per gram of 
creatinine in adult males and >25 mg albumin per gram of creatinine in 
adult females usually signifies chronic renal damage. 
     End-stage renal disease represents a stage of CKD where the 
accumulation of toxins, fluid, and electrolytes normally excreted by the 
kidneys results in the uremic syndrome. This syndrome leads to death 
unless the toxins are removed by renal replacement therapy, using 
dialysis or kidney transplantation. ESRD corresponds to stage 5CKD. 
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Cardiovascular Aspects of Chronic Kidney Disease : 
BACKGROUND : 
             Cardiovascular disease is the main cause of death for patients 
with CKD.  A study conducted by Foley8 and colleagues, found that 
CKD  was associated with a substantially increased incidence of 
congestive heart failure and of atherosclerotic vascular disease events, 
in both diabetics and nondiabetics.  
       Most clinical consequences of cardiac disease result from 
cardiomyopathy or ischemic heart disease. Cardiomyopathy may 
present as an enlarged, dilated left ventricle (LV) with or without 
systolic dysfunction, or as a hypertrophic ventricle with normal left 
ventricular volume and diastolic dysfunction.9   Myocardial ischemia 
may also be present.  Although symptoms of ischemic heart disease are 
most often attributable to the presence of critical coronary artery 
disease (defined as the presence of critical narrowing of the large 
coronary vessels due to atherosclerotic plaques), they may also result 
from non-atherosclerotic disease, associated with small vessel disease 
and LV hypertrophy. Myocardial infarction and angina can result from 
decreased perfusion of the myocardium from either cause. The 
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structure of large arteries can be altered not only by atherogenesis, but 
also by arteriosclerosis.10  
Intramural vascular remodelling occurs as a consequence of 
sustained hemodynamic overload causing conduit vessel dilatation and 
hypertrophy. The consequent increase in vessel stiffness and decreased 
compliance has been shown to contribute adversely to LV structure 
and function, and are strongly associated with an increased risk of 
mortality.11  
             Ischemic symptoms result from coronary artery disease or non-
atherosclerotic ischemic disease. Arteriosclerosis contributes directly 
to ischemic symptoms, LV hypertrophy, and systolic dysfunction by 
increasing cardiac workload. Coronary artery disease predisposes to 
diastolic dysfunction and to systolic failure. Left ventricular 
hypertrophy is nearly always present in dilated cardiomyopathy, but 
also causes diastolic dysfunction with or without normal systolic 
function. 
                Cardiac disease can also result from the development of 
valvular heart disease. Most valvular lesions observed in patients with 
CKD are acquired and develop from dystrophic calcifications of the 
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valvular annulus and leaflets, particularly the aortic and mitral valves. 
Such calcification is now known to be present with a prevalence of up 
to 55% and 39% for the aortic and mitral valves respectively.12,13 
Aortic valve sclerosis is now also associated with an increased 
cardiovascular mortality in the general community.14 
 
FIGURE 1 :  CAUSES OF CARDIAC DEATH IN PATIENTS 
WITH CKD 
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LEFT VENTRICULAR HYPERTROPHY: 
                        Presentation of cardiovascular disease is influenced by 
the duration, severity, and type of renal disease. Left ventricular 
hypertrophy is already evident in 40% of patients with moderate renal 
insufficiency15 and as high as 75% of those with ESRD.16 Both forms 
(concentric and eccentric) are associated with an increased mortality 
risk in dialysis patients and associated risk factors, including 
hypertension, diabetes, tobacco use, and anemia predispose to the 
much more rapid development of symptomatic cardiomyopathy.[17] 
Such patients display a higher incidence of cardiovascular 
abnormalities at an earlier stage of CKD and a younger age, often 
becoming symptomatic or exhibiting significant morbidity well before 
reaching end-stage kidney function. 
                The characteristic changes in LV geometry subsequently are 
a progressive increase over time in both LV volume and LV mass, 
particularly during the first years,[17] and possibly more so in patients 
on peritoneal dialysis. [18] [19] As a result the geometry of the heart 
changes from concentric LV hypertrophy with normal LV volume to 
eccentric LV hypertrophy with dilatation, the end stage of this resulting 
in severe LV dilatation with systolic dysfunction.  
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           The energy-sparing effects of a stable parietal tensile stress 
permits the generation of higher intraventricular pressures without a 
large increase in wall stress. An appropriate relationship is maintained 
between the r/q ratio and systolic pressure generated, so that the 
intrinsic performance of the myocardium is not altered. Initially, 
hypertrophic responses to chronic pressure and/or volume overload are 
also adaptive. Modifications in the heart structure result in an increased 
work capacity while keeping the parietal tensile stress stable, thus 
sparing energy.20 
                 Eventually however LV hypertrophy becomes maladaptive 
with a sustained imbalance between energy expenditure and 
production, resulting in a chronic energy deficit and myocyte death. 
21,22 Consequences of these alterations are electrophysiological 
abnormalities and maintenance of systolic efficiency at the expense of 
impaired diastolic filling. Eventually, in conditions of chronic and 
sustained overload, the deleterious effects of hypertrophy, increased 
LV chamber pressure and fibrosis dominate, leading to the 
development of cardiomyopathy and LV failure.22 
                  Interstitial myocardial fibrosis is a prominent finding in CKD23. 
The extent of myocardial fibrosis in dialysis patients is more marked 
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than in patients with diabetes mellitus or essential hypertension with 
similar LV mass.24  
This is seen particularly in LV hypertrophy, more so in pressure 
than in volume overload, and is exacerbated by many factors, including 
male gender, senescence, ischemia, and effects of hormones such as 
catecholamines, angiotensin II, aldosterone, and transforming growth 
factors.25 
LV functional disturbances : 
Diastolic dysfunction: 
CKD patients with LV hypertrophy often have some impairment 
in diastolic function. The degree of disturbance is probably more than 
that observed in those with hypertensive heart disease,57 but milder 
than that observed in those with hypertrophic cardiomyopathy.23,26,27 
The abnormal ventricular filling in uremia results from increased LV 
stiffness caused by intramyocardial fibrosis and associated delayed 
relaxation. By virtue of an increase in LV stiffness, small changes in 
volume result in large changes in LV pressure, thus predisposing to 
symptomatic pulmonary edema.28 
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Systolic dysfunction : 
           Decreased systolic function may be observed in pre dialysis 
patients with cardiac disease or in patients with prolonged and marked 
hemodynamic overload. Approximately 15% of patients have systolic 
dysfunction by the time they reach stage 5.15  
             Renal transplantation has  been shown to normalize systolic 
function in CKD patients with systolic dysfunction and subsequently to 
reduce but not normalize LV mass index,29,30 although such 
improvement has not yet been shown to confer a survival benefit.31                                                     
Coronary artery disease: 
           Characterized by critical stenoses of the major coronary arteries, 
is highly prevalent in the CKD population, irrespective of underlying 
disease state such as diabetes and hypertension. Recently, two factors 
have received particular attention for their contribution to the 
development of atheroma in CKD:  inflammation and vascular wall 
calcification. 
             Inflammation in general, and C-reactive protein (CRP) 
specifically, may contribute directly to the pathogenesis of 
atherosclerosis and its complications in patients with CKD. CRP has 
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been shown to bind to damaged cells promoting activation of the 
complement system32; it displays calcium-dependent in vitro binding 
and aggregation of LDL and VLDL,33 and is a potent stimulator of 
tissue factor by monocytes.34Epidemiological studies support its 
pathogenetic role as a cardiovascular risk factor in the general 
community, 35,36,37 which may be amenable to intervention by agents 
such as aspirin36 and pravastatin.38  
           In CKD, the source of the (sometimes marked) elevation in CRP 
is uncertain. Potential sources include back filtration of endotoxin 
during dialysis,39 type of vascular access type,40 unrecognized 
infection, or bio-incompatibility of peritoneal dialysate.41 C-reactive 
protein levels have been shown to have a powerful predictive capacity 
for mortality in both hemodialysis and peritoneal dialysis patients,42 
and to be an independent predictor of the number of atherosclerotic 
plaques and intima-media thickness in carotid arteries of 
hemodialysis43 and predialysis patients,44 respectively. 
                The deposition of calcium in vessel walls in patients with 
CKD has received greater attention nowadays. London and colleagues 
have recently examined the differences between intimal and medial 
aortic calcification.45 Intimal calcification is associated with older age, 
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and a history or high risk of atherosclerosis, and medial calcification 
with younger age, lower risk of atherosclerosis, longer duration of 
hemodialysis, and serum calcium-phosphate abnormalities. Medial 
calcification implies arteriosclerosis with noncompliance of the large 
conduit vessels. 
FIGURE 3: CAUSES OF ISCHEMIC HEART DISEASE IN 
CKD: 
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Valvular lesions : 
        Most valvular lesions observed in patients with CKD are acquired 
and develop from dystrophic calcification of the valvular annulus and 
leaflets, particularly the aortic and mitral valves.46 Although most 
studies have identified abnormalities in calcium phosphate metabolism 
as the predominant underlying risk factor, additional factors include 
specific involvement of the posterior cusp, left atrial dilatation, 
duration of dialysis, and duration of pre-dialysis systolic hypertension. 
Factors associated with a decreased survival include severity of 
calcification, mitral regurgitation, and reduced left ventricular function. 
47,48,49,50 
Pericardial Disease: 
Pericardial pain with respiratory accentuation, accompanied by a 
friction rub, is diagnostic of uremic pericarditis. Classic 
electrocardiographic abnormalities include PR-interval depression and 
diffuse ST-segment elevation. Pericarditis can be accompanied by 
pericardial effusion that is seen on echocardiography and can rarely 
lead to tamponade. However, the pericardial effusion can be 
asymptomatic, and pericarditis can be seen without significant 
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effusion. Pericarditis is observed in advanced uremia, and with the 
advent of timely initiation of dialysis, is not as common as it once was. 
 
RISK FACTORS FOR CARDIAC DYSFUNCTION IN CKD : 
Effect of ageing : 
           In a study conducted by Ya Ting Lee and colleagues in 2008 51 , 
they assessed the presence of Chronic Kidney Disease and subsequent 
changes of LV Geometry (LVG) over 4 Years in an apparently healthy 
population aged 60 and older. The prevalences of concentric 
remodelling, eccentric hypertrophy and concentric hypertrophy were 
significantly increased after 4 years. The LVG changes were only 
significant in subjects with CKD at baseline . If we stratified subjects 
into those with favorable (normal and concentric remodeling) and 
those with unfavorable LVG (eccentric hypertrophy and concentric 
hypertrophy), the presence of CKD was an independent predictor for 
unfavorable LVG after 4 years both in univariate and multivariate 
analysis. 
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Anemia : 
            Anemia in  patients with CKD is a predominant manifestation, 
with high frequency but of moderate degree. The most likely cause is 
inadequate erythropoietin production52. Anaemia significantly worsens 
the cardiac function especially in patients on dialysis.52 The 
morphologic feature of anemia consisted of: normochromic-
normocytic (80%), hypochromic-microcytic (15%) and macrocytic 
anemia (5%)53. 
                In a study conducted in Chennai , India54, severity of anemia 
is found to have a significant correlation with LVH and secondary 
hyperparathyroidism in these patients. 
CRP : 
               CRP is probably the most notorious inflammatory marker in 
CKD. It was first described in the 1930s for its role in serologic 
reactions to pneumococcal pneumonia. Interpretations of serum CRP 
levels and atherosclerotic cardiovascular disease61 
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Serum CRP Levels (mg/L)              Interpretation 
 
<1                                                   Normal 
 
1 to 3                                             Possibly increased     
Cardiovascular  risk  
  
 
3 to 10     Highly likely increased   
     Cardiovascular risk, common in  
stage 3 CKD 
 
10 to 50                                             Common in stage 4 & 5 CKD 
 
>50                                                     Acute infection/inflammation  
Usually temporary.  
Dyslipidemia : 
The pattern of lipid profile did not change with severity of 
disease 62 and dyslipidaemia in patients were more in triglycerides, 
68.3% and HDL, 63.5% than in TC, 22.2% and LDL, 17.5%.  
Dyslipidaemia does not only accelerate atherosclerosis in these patients 
but also progresses the renal disease. It is important to screen all 
patients with CKD for dyslipidaemias and treat them appropriately as 
they are considered “a very highrisk” group for cardiovascular disease. 
The target LDL should be maintained below 100 mg/ dl and target non 
HDL below 130 mg / dl63.  
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Hypoalbuminemia : 
              Hypoalbuminemia is associated with LV dilatation and 
predisposes to both de novo cardiac failure and ischemic heart 
disease.64 It is more characteristic of peritoneal dialysis than of 
hemodialysis patients, and in patients treated with each modality 
disease may result from different mechanisms. It is in fact likely that 
the path to death is different in hemodialysis patients, as a higher 
proportion develops cardiac failure, which predisposes to earlier death. 
In renal transplant recipients, hypoalbuminemia is an independent risk 
factor for the development of both de novo cardiac failure and 
ischemic heart disease, a similar observation to that made in dialysis 
patients. 65 
Hypertension : 
                It is probably the most common predictor of cardiovascular 
morbidity. Uncontrolled hypertension is by itself a significant risk 
factor for patients with CKD. Hypertension correlates well with LV 
mass (LVM). This has been proved in several studies.65,67,68  
Hypertension usually develops early during the course of CKD and is 
associated with adverse outcomes, including the development of 
ventricular hypertrophy and a more rapid loss of renal function. Many 
studies have shown a relationship between the level of blood pressure 
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and the rate of progression of  both diabetic and non-diabetic kidney 
disease. Left ventricular hypertrophy and dilated cardiomyopathy are 
among the strongest risk factors for cardiovascular morbidity and 
mortality in patients with CKD and are thought to be related primarily, 
but not exclusively, to prolonged hypertension and ECFV overload.  
              The absence of hypertension may signify the presence of a 
salt-wasting form of renal disease, the effect of antihypertensive 
therapy, or volume depletion or may signify poor left ventricular 
function. Chronic ECFV overload is also a contributor to hypertension, 
and improvement in blood pressure can often be seen with the use of 
oral sodium restriction, diuretics, and fluid removal with dialysis. 
However , because of activation of the renin-angiotensin-aldosterone 
axis and other disturbances in the balance of vasoconstrictors and 
vasodilators, some patients remain hypertensive despite ECFV status. 
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AIMS AND OBJECTIVES 
1. To assess the cardiac status in non diabetic, non smoker chronic 
kidney disease patients in our hospital. 
2. To screen these patients for cardiac risk factors  
3. To compare the different methods of estimating LV mass 
including  LV mass obtained by conventional echocardiography, 
LV mass adjusted to body surface area and LV mass adjusted to 
height and correlate the LV mass in CKD patients and controls. 
4. To assess the effect of uncontrolled hypertension on LV mass in 
these individuals. 
5. To assess diastolic and systolic dysfunction in these individuals. 
6. To evaluate the usefulness of Tissue Doppler imaging (TDI) 
over conventional echocardiography for cardiac assessment in 
CKD patients. 
7. To correlate LV mass with the severity of CKD.  
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MATERIALS AND METHODS 
Setting :   Department of Medicine,  
Government Rajaji Hospital. 
Design :   Descriptive study. 
Period of study :  July 2010 to December 2010. 
Ethical approval :  Obtained from ethical committee headed by The 
Dean,  Government Rajaji Hospital, Madurai. 
Consent :   Informed consent obtained from all patients 
Statistical  
software :  SPSS Version 17.0 
Study population: OP and IP patients in Medicine and Nephrology  
Departments. 
Cases : 
 
Inclusion criteria : 
      (1). All cases of non diabetic and non smoker chronic kidney 
disease. 
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Exclusion criteria : 
1. Patients with H/o coronary artery disease, valvular heart disease 
or any form of congenital heart disease. 
2. Patients with H/o diabetes. 
3. Patients with H/o smoking. 
4. Patients with evidence of diabetic retinopathy.                                                         
5. Patients with active or recent infection over the past 3 weeks. 
6. Patients on hemodialysis. 
7. Patients with A-V fistulas. 
8. Patients on erythropoietin treatment. 
9. Patients with poor echo window. 
10. Patients not giving consent. 
65 CKD patients were taken as cases and 20 healthy volunteers 
were taken as controls. Informed consent was obtained from all the 
patients. A meticulous history was taken regarding the duration of 
CKD, duration of hypertension, family history of diabetes, 
hypertension and CKD. The presence of complaints suggestive of 
volume overload and uraemic symptoms   were carefully elicited. 
The fundus was carefully examined for the presence of any 
evidence of diabetic retinopathy and those cases were excluded from 
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the study. Meticulous blood pressure recording including 3 recordings 
in sitting posture in left upper arm and the mean value of the three was 
taken as blood pressure. Pulse pressure is calculated as the difference 
between systolic and diastolic blood pressure.  
The height and weight of the patient were measured and the 
body surface area is calculated using the formula of DuBois and 
DuBois: 
BSA = (W 0.425 x H 0.725) x 0.007184 
where the weight is in kilograms and the height is in centimeters.  
All patients underwent the following blood investigations 
including blood sugar, urea, serum creatinine, ESR, CRP, Hb%, TGL. 
Patients whose random blood sugar was more than 140 were further 
evaluated with fasting and post prandial blood sugar and if found to be 
abnormal were eliminated from the study. 
eGFR was calculated from serum creatinine values using 1. Cockroft 
Gault equation :                        
Creatinine    (140-age) x bodyweight (kg) 
clearance =      x 0.85 (for women) 
      72 x S.Creat  (mg/dl)  
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and also using 2. MDRD formula 
Estimated GFR (mL/min per 1.73 m2) = 1.86 x (PCr)–1.154 x (age)–0.203 
Multiply by 0.742 for women,  Multiply by 1.21 for African 
Americans.  
NKF-KDOQI staging of CKD was applied using MDRD formula and 
stage of CKD is determined. Electrocardiography(ECG) was done in 
all patients to look for evidence of  LVH, electrolyte disturbances, and 
coronary artery disease 
Echocardiography : 
Basic principles : 
It is a simple, non invasive investigation widely available which 
gives accurate measurement of cardiac function and anatomy of heart. 
It uses ultrasound to study the disposition and movement of valves and 
other structures within the heart. It depends on the reflection of 
ultrasound waves at interfaces between blood and more solid tissues. 
In M mode echocardiography, the ultrasound waves are focussed 
into a narrow beam and the output is a graph against time of the 
movement, relative to the chest wall of those structures through which 
31 
 
the beam passes. Accurate measurements can be made of cardiac 
dimensions. 
          In 2 D echocardiography, the ultrasound beam was swung back 
and front over an arc or sector and the resulting information is 
synthesised into a two dimensional map or picture of the position of 
the reflecting structures on a screen. The picture is the equivalent of a 
slice through the heart. 
        In real time echocardiography, the beam oscillates very rapidly 
and the ultrasound image accurately produces the movement of 
structures in the living heart. This is useful for assessing intracardiac 
mass and vegetations. 
Doppler echocardiography depends on the fact that sound waves 
reflected from moving objects such as intracardiac red blood 
cells(RBC’s) undergo a frequency shift. This can be used to detect the 
direction and speed of movement of RBC’s and thus of the blood in 
heart. 
           Continuous wave Doppler uses a narrow beam of ultrasound in a 
way analogous to M mode echocardiography. 
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          Pulsed wave Doppler can sample movement of  blood at 
different depths beneath the transducer and is frequently combined 
with 2 D echocardiography as to examine blood flow in relation to 
cardiac anatomy. Gradients of flow across valves can be calculated 
using Doppler. Cardiac output can also be measured. 
   Tissue Doppler imaging has the advantage of more accuracy in 
assessing diastolic and systolic dysfunction than conventional 
echocardiography. 
          All patients in the study (both cases and controls) underwent 
echocardiography both 2D and TDI using PHILIPS IE 33 
ECHOCARDIOGRAPHY machine and cardiac function is assessed.   
Echocardiographic parameters assessed: 
Left Ventricular Mass Measurement : 
Left ventricular mass is generally calculated as the difference 
between the epicardium delimited volume and the left ventricular 
chamber volume multiplied by an estimate of myocardial density. 
Following this principle, several methodologies have been used to 
calculate left ventricular mass.  
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          Both M-mode and two-dimensional imaging can be employed to 
calculate left ventricular mass. M-mode imaging allows better 
endocardial border definition as it has greater resolution due to higher 
frame-rate, as long as adequate ultrasound beam positioning is ensured 
and ventricle shape approaches normality. Two-dimensional imaging, 
on the other hand, depicts the "real" ventricular shape and identifies 
regional motion abnormalities. However, the quality of two-
dimensional imaging may be limited due to both lower lateral 
resolution and frame-rate. Two-dimensional images are usually 
acquired both in parasternal and apical views, depending on the 
geometrical formulas that are used.  
Devereux and colleagues proposed a new adjusted equation, 
using the ASE convention and it is so far widely accepted. 
 LV mass (ASE): 0.8 (1.04 ([LVIDD + PWTD + IVSTD]3- 
[LVIDD]3))+ 0.6 g. 
           The body surface area correction, using the Dubois formula , 
reduces variability due to body size and gender , but this index 
underestimates LV mass in the upper range of the body surface area 
distribution. Adjustment of LV mass with body surface area would 
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imply that obese patients are expected to have higher LV mass 
estimations per se. 
           In this scenario, height-based adjustments can more accurately 
estimate LV mass and the resulting cardiovascular risk associated with 
LVH in the obese. Height to the power 2.7, derived from regression 
models in normal samples from De Simone and co-workers, appears to 
offer the most accurate estimation of LV hypertrophy and risk factors 
for pathologic changes in the heart structure, particularly in obese 
subjects.  
            Zoccali and colleagues found LVH indexed by height2.7 to be a 
better predictor of cardiovascular events than LVH indexed using body 
surface area.  
           Liao and colleagues studied 988 patients and identified 
progressive increments in death rates with both body surface area and 
with height2.7 indexing criteria. Subjects simultaneously classified as 
LVH with body surface area and height2.7 criteria had increased 
average LV mass and a 3-fold increase in death rates, while those 
classified as LVH only when indexed by bsa had no increase in future 
cardiovascular events. 
35 
 
In our study LV mass is determined by M mode 
echocardiography and is adjusted to body surface area and also to 
height to the power of 2.7. 
The cut off values for LVH are as adopted from American 
College of Echocardiography guidelines.        
LV mass : 
Normal LV mass in males is < 201 grams and in females, < 151. 
Mild LVH in males is 201 to 227 grams and in females 151 to 171. 
Moderate LVH in males is 228 to 254 and in females 172 to 192. 
Severe LVH in males is ≥  255 and in females ≥  193. 
LVMI (LV mass adjusted to body surface area) : 
Normal LVMI in males is < 103 g/m2 and in females, < 89 g/m2. 
Mild LVH in males is 103 to 116 g/m2 and in females 89 to 100 g/m2. 
Moderate LVH in males is 117 to 131 g/m2 and in females 101 to 112 
g/m2. 
Severe LVH in males is ≥ 131 g/m2 and in females ≥ 113 g/m2. 
LV mass adjusted to height2.7 : 
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Normal LV mass is <49.2 g and in females <46.7. 
Mild LVH is 49.2 to 60 and in females 46.7 to 55. 
Moderate LVH in males is 60 to 80 and in females 55 to 65. 
Severe LVH in males is > 80 and in females >66. 
This is in accordance with American College of Cardiology and 
American Society of  Echocardiography guidelines. 
LV Ejection Fraction measurement (LVEF) : 
             LVEF as determined by LV volumes in apical 2 chamber view. 
LV volumes were measured by area – length method both in end 
diastole (LVVd) and end systole (LVVs). 
            LVEF = (LVVd – LVVs) / LVVd. 
The mean LVEF as per recent ASE guidelines were 63.8± 5. In our 
study, cases having less than 55 % are taken as having systolic 
dysfunction. 
E/A ratio : 
            Diastolic dysfunction was determined by 2 D echocardiography 
by determining ratio of peak early diastole velocity (E) divided by peak 
atrial filling velocity of LV(A). Normal value of E was                          
37 
 
0.61 m/ ± 0.14 and A was 0.48 m/ sec ± 0.14 with a normal E/A ratio 
of 1.40±0.54. 
           Diastolic dysfunction was considered when E/A ratio was found 
to be less than 1. 
           But the fallacy in 2 D Doppler is there is pseudo normalisation 
in cases of grade 2 diastolic dysfunction. This can be overcome by 
using Tissue Doppler imaging where value measured is E’/A’ and 
there will not be any pseudo normalisation. 
There are four basic Echocardiographic patterns of diastolic 
heart failure, graded I to IV. 
1. The mildest form is called an abnormal relaxation pattern or 
grade I diastolic dysfunction. On the mitral inflow Doppler 
echocardiogram, there is reversal of the normal E/A ratio. Many 
grade I patients will not have any clinical signs or symptoms of 
heart failure. 
2. Grade II diastolic dysfunction is called pseudonormal filling 
dynamics. This is considered moderate diastolic dysfunction and 
is associated with elevated left atrial filling pressures. These 
patients more commonly have symptoms of heart failure.  
38 
 
3. Grade  III diastolic dysfunction patients will demonstrate 
reversal of their diastolic abnormalities on echocardiogram 
when they perform the Valsalva maneuver and are called 
reversible restrictive diastolic dysfunction. 
4. Grade IV diastolic dysfunction patients will not demonstrate 
reversibility of their echocardiogram abnormalities and are 
therefore called fixed restrictive diastolic dysfunction. 
In our study diastolic function is assessed using both E/A and 
E’/A’. And the results of both these recordings compared. 
          In our study, systolic BP between uncontrolled and controlled 
individuals were compared with LV mass obtained using 2 D echo and 
adjusted for body surface area and height. BP was assumed as 
controlled if SBP was less than 140 with or without anti hypertensives. 
         In our study, the incidence of anaemia, increased triglyceride 
and CRP positivity in between CKD patients and controls were 
compared. 
          Computer analysis of statistical data were obtained using SPSS 
version 17.0 and the results were analysed. 
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RESULTS AND ANALYSIS 
Stage of CKD and LVM : 
Table -1 
   LVM  
   Normal Mild Moderate Severe Total 
Categor
y 
Control Count 13 5 1 1 20 
Percent 65.0% 25.0% 5.0% 5.0% 100.0%
Stages 2,3 Count 8 3 2 2 15 
Percent 53.3% 20.0% 13.3% 13.3% 100.0%
Stages 4,5 Count 19 8 4 19 50 
Percent 38.0% 16.0% 8.0% 38.0% 100.0%
 Total Count 40 16 7 22 85 
Percent 47.1% 18.8% 8.2% 25.9% 100.0%
 
LV mass increases directly in proportion to the severity  of  
CKD. 65 % of controls are having normal LV mass.  5% (1 control) of 
controls had severe LVH. Whereas, in patients with stage 2 and 3 
CKD, it was 13.3% (2 patients) and in stage 4 and 5 CKD, it was 38% 
(19 patients) 
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Stage of CKD and LVMI (bsa) : 
Table -2 
   LVMIbsa 
   Normal Mild Moderate Severe Total 
Category Stages 
2,3 
Count 9 3 2 1 15 
Percent 60.0% 20.0% 13.3% 6.7% 100.0%
Stages 
4,5 
Count 21 12 10 7 50 
Percent 42.0% 24.0% 20.0% 14.0% 100.0%
 Total Count 30 15 12 8 65 
Percent 46.2% 23.1% 18.5% 12.3% 100.0%
 
           LVMI (LVM adjusted to body surface area) varies directly in 
relation to increasing severity of CKD. In patients with stage 2 and 3 
CKD, 13.3% had moderate LVH and 6.7% had severe LVH. Whereas 
in patients with stage 4 and 5 CKD, it increase to 20% and 14% 
respectively. 
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Stage of CKD and LVMHt : 
Table -3 
   LVMht  
   Normal Mild Moderate Severe Total 
Category Control Count 15 3 1 1 20 
Percent 75.0% 15.0% 5.0% 5.0% 100.0%
Stages 
2,3 
Count 9 2 3 1 15 
Percent 60.0% 13.3% 20.0% 6.7% 100.0%
Stages 
4,5 
Count 13 13 9 15 50 
Percent 26.0% 26.0% 18.0% 30.0% 100.0%
 Total Count 37 18 13 17 85 
Percent 43.5% 21.2% 15.3% 20.0% 100.0%
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 18.286 6 .006 
 
A significant correlation exists between stage of CKD and LV mass 
adjusted to height (p value of 0.06) . 75 % of controls are having 
normal LV mass whereas 48 % of patients with stages 4 and 5 CKD 
are having moderate to severe LVH. 
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Systolic BP and LV mass : 
Table -4 
      LVM  
Total       Normal Mild Moderate Severe 
sysBP  Controlled Count 29 11 1 9 50 
Percent 58.0% 22.0% 2.0% 18.0% 100.0%
Uncontrolled Count 11 5 6 13 35 
Percent 31.4% 14.3% 17.1% 37.1% 100.0%
Total Count 40 16 7 22 85 
Percent 47.1% 18.8% 8.2% 25.9% 100.0%
 
  
Value df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-Square 12.387a 3 .006 
 
A significant correlation exists between systolic BP and LV mass with 
a p value of 0.006. 54.2% of patients with uncontrolled BP have 
evidence of moderate to severe LVH. Whereas it is 20 % in those with 
controlled BP. 
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Systolic BP and LVMI (bsa) : 
Table -5 
      LVMIbsa 
Total       Normal Mild Moderate Severe 
sysBP  Controlled Count 34 8 4 4 50 
Percent 68.0% 16.0% 8.0% 8.0% 100.0%
Uncontrolled Count 12 11 8 4 35 
Percent 34.3% 31.4% 22.9% 11.4% 100.0%
Total Count 46 19 12 8 85 
Percent 54.1% 22.4% 14.1% 9.4% 100.0%
 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 9.993a 3 .019 
 
A significant correlation exists between systolic BP and LV mass 
index adjusted to body surface area with a p value of 0.019. 34.3% of 
patients with uncontrolled BP have evidence of moderate to severe 
LVH. Whereas it is 16 % in those with controlled BP. 
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Systolic BP and LVM (ht2.7) 
Table -6 
      LVM /ht2.7  
Total       Normal Mild Moderate Severe 
sysBP Controlled Count 29 10 4 7 50 
Percent 58.0% 20.0% 8.0% 14.0% 100.0%
Uncontrolled Count 8 8 9 10 35 
Percent 22.9% 22.9% 25.7% 28.6% 100.0%
Total Count 37 18 13 17 85 
Percent 43.5% 21.2% 15.3% 20.0% 100.0%
 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 12.331a 3 .006 
 
A significant correlation exists between systolic BP and LV mass 
adjusted to height with a p value of 0.006. 54.3% of patients with 
uncontrolled BP have evidence of moderate to severe LVH. Whereas it 
is 22 % in those with controlled BP. 
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Stage of CKD and E/A 
Table -7 
   EA   
   < 1 >=1 Total 
Category Control Count 1 19 20 
Percent 5.0% 95.0% 100.0% 
Stages 
2,3 
Count 4 11 15 
Percent 26.7% 73.3% 100.0% 
Stages 
4,5 
Count 25 25 50 
Percent 50.0% 50.0% 100.0% 
 Total Count 30 55 85 
Percent 35.3% 64.7% 100.0% 
 
Chi-Square Tests
 Value  df Asymp. 
Sig. (2-
sided) 
Pearson Chi-Square 13.261
a
2 .001 
 
A significant correlation exists between stage of CKD and E/A ratio 
with a p value of 0.001. 5% of controls were having an E/A ratio of 
less than 1. Whereas it was 25.3 % in patients in patients with stage 2 
and 3 CKD and 50% in patients with stage 4 and 5 CKD 
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Stage of CKD and E’/A’ : 
Table - 8 
   E’/A’1   
   < 1 >=1 Total 
Category Control Count 1 19 20 
Percent 5.0% 95.0% 100.0% 
Stages 
2,3 
Count 4 11 15 
Percent 26.7% 73.3% 100.0% 
Stages 
4,5 
Count 41 9 50 
Percent 82.0% 18.0% 100.0% 
 Total Count 46 39 85 
Percent 54.1% 45.9% 100.0% 
 
Chi-Square Tests 
 Value df Asymp. 
Sig. (2-
sided) 
Pearson Chi-Square 39.639
a 
2 .000 
 
A highly significant correlation with a p value of 0.000 was obtained 
between stage of CKD and E’/A’. 5% of controls were having an E/A 
ratio of less than 1. Whereas it was 26.7 % in patients in patients with 
stage 2 and 3 CKD and 82% in patients with stage 4 and 5 CKD. 
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Tissue Doppler imaging using E’/A’ detects more number (82%) of 
diastolic dysfunction when compared to conventional echo (E/A) 
which detects only 50%  . 
Stage of CKD and EF : 
Table -9 
   EF   
   <= 55 >55 Total 
Category Control Count 0 20 20 
Percent .0% 100.0% 100.0% 
Stages 
2,3 
Count 1 14 15 
Percent 6.7% 93.3% 100.0% 
Stages 
4,5 
Count 25 25 50 
Percent 50.0% 50.0% 100.0% 
 Total Count 26 59 85 
Percent 30.6% 69.4% 100.0% 
 
Ejection fraction decreases in direct proportion to severity of CKD. In 
controls, there are no individuals with EF <55 whereas it is 6.7% in 
stages 2 and 3 CKD and it is 50 % in patients with stages 4 and 5 
CKD. EF is one of the markers to assess the severity of renal failure. 
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DISCUSSION 
Cardio vascular disease is the major cause of mortality in 
patients with CKD. Indian CKD patients are more prone to 
cardiovascular disease than in the West due to ethnic, socio economic 
and other cardiovascular risk factors. They tend to develop CKD at 
least 2 decades earlier than their western counterparts and many fail to 
reach the hospital in an earlier stage due to lack of awareness and socio 
economic factors. The burden of CKD is increasing worldwide and it 
has doubled over the past 15 yrs. CKD in Indian scenario is a burden to 
the society and family. 
         Assessment of cardiac function in CKD should be started as soon 
as CKD is diagnosed and should be done periodically to assess the 
prognosis in these patients and early initiation of treatment is 
recommended to halt the progression of disease. LV hypertrophy is an 
independent predictor of mortality in patients with CKD. Emergence of 
grade 3 and 4 diastolic dysfunction and systolic dysfunction has been 
associated with a grave prognosis in patients with CKD. 
 We analysed 65 CKD patients and 20 controls from the 
Department of Medicine and Department of Nephrology from 
Government Rajaji Hospital. Out of CKD patients, males constitute 
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about 57% (number of patients 37) and females were 43% (number of 
patients 28). Among the controls, 2(60%) were males and 8(40%) 
females. 
Age: 
 The minimum age in control group was 28 and the maximum 
age 61 with mean age of 43.35. In CKD group, minimum age was 28 
and maximum age was 66. Mean age of CKD patients analysed was 
43.43. The CKD patients in our study and controls were comparable in 
age and sex. 
         As per Indian study published by Dr.S.Agarwal from New Delhi 
in 2003, the mean age of Indian CKD was found to be 35-45 yrs. Mean 
age of western CKD population was 51-60 yrs. Our study correlates 
well with the findings of Indian literature. It is probably attributed to 
increased prevalence of streptococcal infections in Indian scenario 
whereas in western countries diabetes and hypertension in old age are 
responsible for majority of CKD. As per our study, CKD is a problem 
in middle age group. 
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Anaemia : 
         The  Hb level in controls varied from 8 to 14gm with a mean of 
11.02gm. In stages 4 & 5 CKD the Hb levels varied from 4 to 12gm 
with a mean 8.46gm.  In 2005 Suega K. Bhakta69  confirmed an 
increased prevalence of anaemia with worsening degrees of renal 
failure. The severity of anemia correlates with the severity of renal 
failure in our study.  
Anaemia is one of the most important factors worsening cardiac 
status and correction of anemia with iron supplements and 
erythropoietin in CKD population is recommended to prevent cardiac 
mortality. 
ESR : 
Fernandes et al found ESR does not correlate with degree of 
anemia in CKD population. In our study ESR did not correlate with the 
severity of anemia. A raised ESR is a marker of low grade chronic 
inflammation in CKD, especially in hemodialyzed patients.72 
CRP : 
            CRP was positive in 21% (14 patients) of CKD patients in our 
study. In none of the controls, it was positive. CRP carries a great 
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impact on cardiovascular mortality in CKD patients and the level of 
CRP correlates well with adverse cardiovascular outcome. 
Triglyceride : 
           The  mean triglyceride levels in stages 4 & 5 CKD is 200.04 
whereas in controls it is 181.15. But no significant relation can be 
obtained between the two values. Triglycerides do increase with 
increasing stages of CKD compared to controls and early institution of 
treatment protects against both cardiovascular complications and 
further worsening of renal failure. 
LV hypertrophy : 
LV mass : 
LV mass predicts mortality in general. We try to correlate LB 
mass to the severity of CKD. 5% of controls, (1 control) had severe 
LVH. In patients with stage 2 and 3 CKD, it was 13.3%. In stage 4 and 
5 CKD, it was 38%. It correlates well with another study published in 
Indian journal of Nephrology in 2003 in which study the mean LV 
mass varies directly in relation to stage of CKD. 
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indexed to BSA. Indexation to BSA offsets the independent impact of 
obesity on LV mass which decrease sensitivity of LV mass index for 
measuring LV mass. 
LV mass adjusted to height2.7 : 
               A significant correlation exists between stage of CKD and 
LV mass adjusted to height (p value of 0.06) . 75 % of controls are 
having normal LV mass whereas 48 % of patients with stages 4 and 5 
CKD are having moderate to severe LVH. 
This is in accordance with other studies including the report 
from the Strong Heart Study group showed that the presence of LVH 
identified by LV mass normalized for height to allometric powers is 
associated with higher incident cardiovascular events than is LVH 
detected by normalization for body surface area75. Another study74 
concludes that the highest prevalence of LVH was when LVM was 
indexed to the power of 2.7. 
Systolic BP : 
A significant correlation exists between systolic BP and LV 
mass with a p value of 0.006. 54.2% of patients with uncontrolled BP 
have evidence of moderate to severe LVH. Whereas it is 20 % in those 
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with controlled BP. This is in accordance with harrisons textbook of 
internal medicine 17th edition, which states that hypertension as the 
single most important predictor of LV mass. 
          Significant correlation is also obtained between uncontrolled 
systolic BP and LV mass index (0.019) and LV mass adjusted to 
height(0.006) 
Management of systemic hypertension drastically improves the 
morbidity and mortality in CKD patients irrespective of cause. Target 
BP to be maintained less than 130/80 and 125/75 in those with 
proteinuria. 
E / A ratio : 
A significant correlation exists between stage of CKD and E/A 
ratio with a p value of 0.001. 5% of controls were having an E/A ratio 
of less than 1. Whereas it was 25.3 % in patients in patients with stage 
2 and 3 CKD and  50% in patients with stage 4 and 5 CKD. 
E’/A’ ratio : 
A highly significant correlation with a p value of 0.000 was 
obtained between stage of CKD and E’/A’. 5% of controls were having 
an E/A ratio of less than 1. Whereas it was 26.7 % in patients in 
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patients with stage 2 and 3 CKD and 82% in patients with stage 4 and 
5 CKD. 
           Tissue Doppler imaging using E’/A’ detects more number (82%) 
of diastolic dysfunction when compared to conventional echo(E/A) 
which detects only 50%  . As there is pseudo normalisation of flow 
pattern, it is difficult to interpret whether a normal E/A ratio is 
associated with normal cardiac function or grade 2 diastolic 
dysfunction. This is overcome by Tissue Doppler imaging. This was 
supported by a study from Shirley Yumi Hayashi76, from Sweden who 
compared tissue Doppler with conventional echocardiography in CKD 
patients and they concluded that in patients with advanced renal 
failure, TDI revealed more accentuated diastolic dysfunction 
associated with increased systolic blood pressure (SBP) and increased 
levels of PTH. TDI also demonstrated disturbances in contractility and 
contraction in patients with LVH, which could not be detected by 
conventional echocardiography. 
LVEF:  
Ejection fraction decreases in direct proportion to severity of 
CKD. In controls, there are no individuals with EF <55. Whereas it is 
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6.7% in stages 2 and 3 CKD and it is 50 % in patients with stages 4 
and 5 CKD. 
          The prevalence of diastolic dysfunction is 82 % which is much 
more than systolic dysfunction of 50 %. It suggests that diastolic 
dysfunction was the first to appear in renal failure. 
         Mitral regurgitation occurred in 6 patients in our study. Aortic 
regurgitation in 3 and tricuspid regurgitation in 2 patients.   pericardial 
effusion was observed in 4 patients in the study. 
 
 
 
 
 
 
 
 
 
57 
 
SUMMARY 
Patients with chronic kidney disease (CKD) most often present 
with non specific complaints or often asymptomatic detected by 
routine biochemical investigations. A high degree of suspicion is 
needed to detect early stages of CKD. Any patient diagnosed as CKD 
irrespective of the stage should be completely evaluated for 
establishing the cause of CKD and also establish the various 
hemodynamic abnormalities associated with CKD. 
          In particular, importance should be given for evaluating the 
cardio vascular risk factors and cardiac function in CKD patients. 
           Co morbid conditions which worsen the cardiac status such as 
alcohol, smoking should be curtailed. In diabetics, meticulous control 
of blood sugar is mandatory taking care to avoid hypoglycaemia. 
Anaemia as shown in our study is an important co morbid condition 
increasing in severity with stage of CKD. All patients should be 
evaluated for the cause of anaemia and treated accordingly, if needed 
with erythropoietin. 
           Hypertension, especially if uncontrolled, as shown in our study 
correlates significantly with  LV mass and in turn  cardiac mortality. 
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Echocardiography is one of the best non invasive means of evaluating 
cardiac function in patients with CKD. LV mass, diastolic and systolic 
dysfunction correlates with stage of CKD. 
The following points were noted in our study : 
1. Anaemia increases in severity with stage of CKD. It further 
worsens the cardiac function irrespective of pre existing cardiac 
status. 
2. Hypertension, especially if uncontrolled significantly correlates 
with LV mass with a p value of 0.006 
3. LV mass increases directly in proportion to stage of CKD. 
4. LV mass adjusted to body surface area called as LV mass index 
increases in direct proportion to stage of CKD but statistically 
significant relation could not be obtained. 
5. LV mass adjusted to height to the power of 2.7 has significant 
correlation with stage of CKD. 
6. LV mass index adjusted to height is the best predictor of LV 
mass in patients with CKD and correlates directly to 
cardiovascular mortality. 
7. E/A ratio predicts the diastolic dysfunction which worsens 
progressively with increasing stages of CKD. 
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8. E’/A’ measured by tissue Doppler imaging correlates with 
diastolic dysfunction which worsens with stage of CKD. 
9. E’/A’ is a better predictor of  diastolic dysfunction than E/A as it 
avoids the fallacy of pseudo normalisation. 
10. EF worsens with advancing kidney disease and predicts systolic 
dysfunction. 
11. Other cardiac lesions infrequently noted include regurgitant 
lesions of mitral, tricuspid and aortic valves. 
12. Pericardial effusion was noted in 4 patients in the study. 
13. No case of aortic / mitral annular calcifications are noted in the 
study. 
 
Echocardiography provides a valuable tool in CKD patients even if 
asymptomatic and should be regularly followed up.  
Echocardiographic evaluation should be included as a routine 
investigation in CKD patients. 
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CONCLUSION 
The burden of cardiovascular disease in patients with chronic 
kidney disease is high. Multiple traditional cardiac risk factors and 
uraemia related risk factors coexist. 
           Echocardiography should be performed early in the course of 
CKD. Tissue Doppler imaging should be performed in all cases for 
accurate assessment of cardiac status. In the cardiovascular system, LV 
hypertrophy, LV diastolic and systolic dysfunction predominate and 
worsens with stage of CKD. Strict control of BP is advocated. 
Anaemia should be promptly corrected. Treatment of dyslipidemia is 
warranted in those deserving treatment. CRP is an important risk factor 
and should be duly monitored and treated with aspirin and statins. 
Early institution of dialysis partially protects against these cardiac 
complications and improves cardiac function. 
1) CKD is a burden in middle age group in our study. 
2) Cardiac mortality is high in CKD patients.                                                           
3) Anemia correlates with cardiac function and correction of 
anemia decreases cardiac mortality. 
4) Hypertension statistically correlates with LV mass. 
5) Diastolic and systolic dysfunction worsens with stage of CKD. 
6) Echocardiographic evaluation is a must in CKD population. 
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